All In MedTech

Device Trial Radar · NCT06833060

Transscleral Selective Laser Trabeculoplasty Project

Exploratory Clinical Study of a Laser-OCT Integrated System With Eye Tracking to Treat Glaucoma and OHT With Transscleral Selective Laser Trabeculoplasty Technology A Pilot Study

Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

Jun 19, 2025

Primary completion

Jul 30, 2026

Study completion Jul 30, 2026

Sponsor

Lead sponsor
Lumibird Medical (Quantel Medical, Ellex Medical, Optotek)Not on our public-company list
Sponsor type
Industry
Collaborators
Quantel Medical
First posted
Feb 18, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Device feasibility
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to determine how safe and effective (how well it works) the ELLEX TSLT device is for the treatment of Glaucoma and Ocular Hypertension using Transscleral Selective Laser Trabeculoplasty. Selective Laser Trabeculoplasty (SLT) is a type of laser therapy that uses short pulses of low-energy light to lower eye pressure. This treatment uses a lens in contact with the front part of the eye (called cornea) which may lead to complications. Transscleral Selective Laser Trabeculoplasty allows the doctor to perform the laser treatment without the lens coming into contact with the cornea, potentially offering a simpler, quicker and safer approach for both participants and doctors. Participants will be required to attend four study visits. The first visit will assess the disease, the second will involve the TSLT laser treatment for the participant's condition (glaucoma or ocular hypertension), and the final two visits, at 1 day and 30 days post-treatment, will evaluate the treatment's efficacy and the procedure's safety.

Conditions

  • Glaucoma,Open-Angle
  • Ocular Hypertension (OH)

Interventions

  • Selective Laser TrabeculoplastyDevice

    Treatment of Glaucoma or Ocular Hypertension participants using Transscleral Selective Laser Trabeculoplasty

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Treatment-Related Adverse EventsTime frame: From treatment to 30 days after

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Central Adelaide Local Health Network - Royal Adelaide Hospital

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.